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ABSTRACT 
Background. The second CONCORD study (CONCORD-2) reported that 5-year net survival for lung 
cancer was low (10%–20%) during 1995–2009 in most countries, including the United States, which 
was at the higher end of this range. 
Methods. Using data from CONCORD-2, we analyzed net survival among lung cancer patients (aged 
15–99 years) diagnosed in 37 states, covering 80% of the US population. We corrected survival for 
background mortality using state- and race-specific life tables, and age-standardized the all-ages 
estimates using International Cancer Survival Standard weights. We estimated net survival for patients 
diagnosed during 2001–2003 and 2004–2009 at 1, 3, and 5 years after diagnosis by race (all, black, and 
white), SEER Summary Stage 2000, and state. 
Results. Five-year net survival increased from 16.4% (95% CI, 16.3%–16.5%) in 2001–2003 to 19.0% 
(18.8%–19.1%) in 2004–2009, with increases in most states and among both blacks and whites. In 
2004–2009, 5-year survival was lower among blacks (14.9%) than whites (19.4%), and ranged by state 
from 14.5% to 25.2%. 
Conclusion. Lung cancer survival improved slightly from 2001–2003 to 2004–2009, but was still low, 
with differences by race and state. Efforts to control well-established risk factors would be expected to 
have the greatest impact on reducing the burden of lung cancer, and efforts to ensure all patients receive 
timely and appropriate treatment might reduce the differences in survival by race and state. 
Keywords: Lung neoplasms; survival; cancer registries; survival; stage; race; disparities; trends 
 
Précis: 
Lung cancer survival improved slightly during 2001–2009, but remained lower among blacks than 
whites. Efforts to control well-established risk factors would be expected to have the greatest impact on 
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reducing the burden of lung cancer, and efforts to ensure all patients receive timely and appropriate 
treatment might reduce the differences in survival by race and state. 
 
Abbreviations 
NCI, National Cancer Institute; NCCCP, National Comprehensive Cancer Control Program; NPCR, 
National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program. 
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INTRODUCTION 
In the United States, lung cancer accounts for approximately 14% of all invasive cancers 
diagnosed each year and 27% of all cancer-related deaths.1 Lung cancer incidence and mortality rates 
vary by gender and race.1,2 Among males, lung cancer incidence peaked in 1982, and mortality peaked 
in 1991.2 Among females, mortality peaked in 2003, and incidence peaked in 2006.2 Lung cancer 
incidence and mortality rates are currently decreasing slowly, but the rates are higher among black males 
than white males, and lower among black females than white females.1,2 By 2020, the numbers of lung 
cancer cases and deaths in the United States are projected to increase because of the aging white 
population and population growth in the black population.3,4 
Population-based cancer survival provides an indicator of the overall effectiveness of the health 
care system to deliver screening, early diagnosis, and evidenced-based treatment services to all people in 
the population being served.5 Survival differences between populations may be attributable to disparities 
in access to early diagnosis and optimal treatment.6 
The second CONCORD study (CONCORD-2) reported survival for patients with cancer 
diagnosed from 1995 through 2009 in 67 countries, and enabled the comparison of survival of patients 
in the United States with other countries.6,7 The CONCORD-2 study is the largest study to date on lung 
cancer survival, both in the United States and world-wide. During 1995–2009, the 5-year net survival for 
patients diagnosed with lung cancer was low in most countries (10% to 20%).6 Survival in the United 
States was at the higher end of this range.6 
In the current study, we conduct a more detailed analysis of the US data from the CONCORD-2 
study. We describe and discuss trends in net survival among patients diagnosed with lung cancer by 
race, stage, and state. We also discuss how population-based lung cancer survival might be used to help 
inform comprehensive cancer control.8 
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Materials and Methods 
Data source 
We analyzed the US lung cancer data from the CONCORD-2 study, which included cases reported by 
37 state-wide cancer registries that covered approximately 80% of the US population, and that consented 
to inclusion of their data in the more detailed analyses reported here.7 We analyzed individual tumor 
records for adults (men and women aged 15–99 years) who were diagnosed with a primary invasive 
cancer of the lung and bronchus (International Classification of Disease Oncology 3rd edition9 
topography codes: C34.0-C34.3; C34.8-C34.9) during 2001–2009, and followed up to December 31, 
2009, regardless of whether the patient had had a previous cancer. If a patient was diagnosed with two or 
more cancers of the lung during 2001–2009, we only considered the first cancer in the survival analyses. 
We grouped patients by year of diagnosis into two calendar periods (2001–2003 and 2004–2009) 
to reflect changes in the methods used by US registries to collect SEER Summary Stage (SS) 2000 at 
diagnosis. During 2001–2003, most registries coded stage SS2000 directly from the medical records.10 
During 2004–2009, all registries derived SS2000 using the Collaborative Staging System.11 
 
Survival analyses 
We analysed net survival by race (all, black, white), by stage (SS2000: localized, regional, distant, 
unknown), state, and calendar period of diagnosis. We estimated net survival at 1, 3, and 5 years after 
diagnosis and 95% confidence intervals (CI) using the Pohar Perme estimator.7,12 Net survival can be 
interpreted as the probability of survival up to a given time since diagnosis, after controlling for other 
causes of death (background mortality).7 To control for wide differences in background mortality among 
participating registries, we constructed life tables of all-cause mortality in the general population of each 
state from the number of deaths and the population, by single year of age, sex, calendar year and, where 
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possible, by race (black or white), using a flexible Poisson model.13 These life tables have been 
published.14 
We estimated net survival by two different methods, because patients diagnosed in the two 
calendar periods had different years of follow-up after diagnosis. For patients diagnosed during 2001–
2003, we used the cohort approach, since all patients had been followed for at least five years by 
December 31, 2009. We used the complete approach to estimate net survival for patients diagnosed from 
2004–2009, because five years of follow-up data were not available for all patients. We estimated net 
survival for five age groups (15–44, 45–54, 55–64, 65–74, 75–99 years). We obtained age-standardized 
survival estimates using the International Cancer Survival Standard (ICSS) weights.15 If two or more of 
the five age-specific estimates could not be obtained, we present only the pooled, unstandardized 
survival estimate for all ages combined. We identify unstandardized state estimates using italics in 
tables. 
An appropriate statistical test is not currently available to evaluate whether two net survival 
curves differ significantly.7 We note differences when 95% confidence intervals (CI) for two estimates 
do not overlap. We also present trends, geographic variations, and differences in age-standardized 
survival by race in bar charts and funnel plots.16 Funnel plots of net survival for 2001–2003 and 2004–
2009 provide insight into the variability of lung cancer survival by race and state. They show how much 
a particular survival estimate deviates from the pooled estimate for all registries combined, given the 
precision of each estimate.7,16 We show the pooled estimate of US registries as a horizontal line in the 
funnel plot. 
More details on data and methods are provided in the accompanying article by Allemani et al.7 
 
RESULTS 
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We present the overall results for lung cancer in Tables 1, 2, and 3. We report state-specific results in 
Supplemental Tables 1, 2, and 3. 
 
Distribution of cases by stage, race, and calendar period 
A total of 1,404,724 patients were diagnosed with lung cancer during the period 2001–2009; 86.9% 
were white and 10.2% were black (Table 1). The proportion of patients diagnosed with disease at distant 
stage increased from 46.8% in 2001–2003 to 50.9% in 2004–2009. In contrast, the proportions of 
localized stage (17.5% and 17.7%) and regional stage (24.2% and 23.4%) remained relatively stable 
over time (Table 1). In both time periods, the proportion of blacks diagnosed with localized stage 
disease was lower than for whites, while a higher proportion of blacks were diagnosed at distant stage. 
During 2004–2009, the proportion of patients diagnosed at each stage ranged between states as follows: 
localized (13.1%–21.9%), regional (20.3%–26.3%), and distant (45.4%–59.4%) (Supplemental Table 1). 
 
1-year, 3-year, and 5-year net survival by race and calendar period 
During 2001–2003, the pooled estimate of net survival of all patients combined was 42.5% (95% CI, 
42.4%–42.7%) at 1 year, 21.6% (95% CI, 21.4%–21.7%) at 3 years, and 16.4% (95% CI, 16.3–16.5) at 
5 years. For patients diagnosed during 2004–2009, it had risen to 45.6% (95% CI, 45.5%–45.7%) at 1 
year, 24.5% (95% CI, 24.4%–24.6%) at 3 years, and 19.0% (95% CI, 18.8%–19.1%) at 5 years (Table 
2). Net survival for whites was similar to the overall US net survival at 1, 3, and 5 years, while net 
survival among blacks was about 4-5% lower than for whites at 1, 3, and 5 years. As the general 
direction and magnitude of racial disparities were similar at 1, 3 and 5 years, we present only 5-year net 
survival estimates in the remainder of the results. 
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Among whites in 37 states in 2004–2009, 5-year net survival ranged by state from 15.1%–25.7% 
(Supplemental Table 2). Among blacks in 36 states during 2004–2009, 5-year net survival ranged from 
7.0%–22.7% (data for 5-year net survival among blacks were not available for Montana). 
 
5-year net survival by stage, race, and calendar period 
The pooled estimates of 5-year net survival for the US increased from 50.2% in 2001–2003 to 
55.1% in 2004–2009 for localized stage, from 20.2% to 26.4% for regional stage, and from 3.6% to 
4.8% for distant stage (Table 3). In both time periods, the US estimate of 5-year net survival was 9–10% 
lower among blacks than whites for localized stage, and 3–5% lower for regional stage. Among 34 states 
during 2004–2009, the range in state-specific 5-year net survival was 39.4%–66.4% for patients 
diagnosed at localized stage, 19.1%–34.0% for regional stage, and 2.8%–10.1% for distant stage 
(Supplemental Table 3) (5-year survival estimates by stage were not available for Maryland, Wisconsin, 
or Rhode Island for 2004–2009). 
 
Absolute change in 5-year net survival between 2001–2003 and 2004–2009 
The 5-year net survival in most Northeastern states was higher than the US pooled estimate during both 
2001–2003 and 2004–2009 (Figure 1). In contrast, the 5-year net survival in many states in the South, 
Midwest, and West was lower than the US estimate during both time periods. Between 2001–2003 and 
2004–2009, the absolute change in 5-year net survival increased 0.4-6.3% in 35 states, with a small 
decrease 0.2-0.3% in two states. The absolute increase was greater than 2.6% (the increase in the pooled 
US estimate) in most states in the Northeast. In contrast, the absolute increase was less than 2.6% in 
many states in the South, Midwest, and West. 
 
Funnel plots of 5-year net survival by state 
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Figure 2 shows geographical and racial variation in 5-year net survival by state. Although net survival 
for lung cancer was generally low in all states, in both calendar periods, survival for black patients was 
lower than survival for white patients, and in most states it was lower than the pooled estimate of US 
registries (the horizontal line in the funnel plot). 
 
Discussion 
This study provided lung cancer survival estimates by race and stage for 37 states including 80% of 
the US population. During 2004–2009, the US lung cancer 5-year net survival was at the high end of the 
range for many countries in the CONCORD-2 study,6 and consistent with 5-year relative survival 
estimates previously reported in NPCR17 and SEER registries.2 
Even for a lethal cancer such as lung cancer, survival for blacks was lower than for whites (Table 2) 
and this was true especially for localized cancer (Table 3) for which surgery is the main treatment of 
curative intent. We found that the overall 5-year net survival for lung cancer (19.0%) was 4.2% higher 
than for liver cancer (14.8%),18 but lower than the net survival for the other cancers included in this 
Supplement: stomach (29.0%);19 ovary (41.0%);20 cervix (62.8%);21 rectum (64.0%);22 colon (64.6%);23 
acute lymphoblastic leukemia in children (88.1%);24 breast (88.6%);25 and prostate (96.9%)26 cancer. 
In 2004-2009, we found 5-year net survival for all stages was 4.5% lower among blacks than among 
whites. The racial differences were even more marked for lung cancer diagnosed at a local stage (9.9% 
lower among blacks), 4.7% lower among blacks diagnosed at regional stage, but essentially the same for 
patients diagnosed at a distant stage (only 0.3% lower among blacks). Our results are consistent with 
other reports of racial disparities in lung cancer.2,17,27-29 Reviews suggest that the reasons for the wide 
racial disparities in lung cancer survival are complex and multifactorial, with contributions from 
treatment-related factors such as physician-patient encounters and decision making, and barriers to 
access to high-quality care such as lower patient income or insurance coverage limits.30-32 Unfortunately, 
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although our study highlights two key determinants (race and stage) of survival differences between US 
states, it does not provide definite conclusions about all the factors that may contribute to differences, 
because information on all factors is not available for all cancer patients at a population-based level. It 
would be interesting to analyze the availability of optimal treatment by US state and race. This may be 
possible during the next cycle of CONCORD (CONCORD-3). 
In most states, we observed small but consistent increases in 5-year lung cancer net survival from 
2001–2003 to 2004–2009, even though the study only covers a single decade. Overall, the increase in 5-
year net survival among whites was 2.6%, while the increase in blacks was 1.8%. We also observed 
considerable variation in lung cancer survival between US states. Overall, 5-year net survival ranged 
widely by state from 14.5% to 25.2% during 2004–2009, and ranges in survival were more extensive by 
stage: 39.4%–66.4% for patients diagnosed at localized stage, 19.1%–34.0% for regional stage, and 
2.8%–10.1% for distant stage. We also observed that the change in survival between the two time 
periods ranged by state, from decreased survival in 2 states to an increase of up to 6.3% in the other 35 
states. As with differences by race, our study does not enable definite conclusions about the explanation 
for the differences we observed over time and by geography. 
 
Clinical perspective 
During 2001–2009, a number of improvements occurred in clinical care for lung cancer; for 
example, increased use of video-assisted thoracic surgery,33 intensity modulated radiation therapy,34 and 
targeted therapy, also referred to as precision or personalized treatment.35,36 We could not directly assess 
whether differential access to treatment by race contributed to the racial disparities in survival, because 
we did not have data on the treatment received by each patient, but “if equal treatment [for lung cancer] 
yields equal outcome regardless of race”,37 that is a plausible conclusion. 
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Survival can be improved if treatment can be provided when lung cancer is diagnosed at a 
localized stage.35,38 For the cancers in this Supplement, only patients diagnosed at a localized stage with 
liver cancer had lower 5-year survival (25.7%)18 during 2004–2009 than for lung cancer at localized 
stage (55.1%). In contrast, cancers commonly identified through screening tests (colon, breast and 
prostate cancers) had the highest 5-year survival for localized stage during 2004–2009, at 89.7%,23 
98.3%,25 and 99.9%,26 respectively. For the other cancers in this Supplement, only ovarian cancer had a 
higher proportion of cases (56.8%)20 diagnosed at a distant stage during 2004–2009 than lung cancer 
(50.9%). Cancers commonly identified through screening tests (colon, breast and prostate cancers) 
during 2004–2009 had lower proportions of cases diagnosed at a distant stage, at 19.3%,23 5.2%,25 and 
3.7%,26 respectively. 
Screening with low dose-computed tomography (CT) is now recommended by the US Preventive 
Services Task Force (USPSTF)39 for individuals at high risk for lung cancer, and is covered by 
Medicare.40 However, early detection of lung cancer by screening is unlikely to have contributed to the 
increase in 5-year net survival that we observed for lung cancer, because low dose CT scan was not 
broadly available or recommended during 2001–2009,41 and the USPSTF recommendations and 
Medicare regulations were only issued later. 
In our study, the overall proportion of cases with unknown stage decreased from 11.5% in 2001–
2003 to 8.0% in 2004–2009. This is an encouraging finding because accurate lung cancer staging35 is 
needed to guide therapy selection. Although this decrease is consistent with an increase in accuracy over 
time in lung cancer staging, the observed changes could be an artifact related to changes in staging 
methods between the two calendar periods. Alternatively, cases with unknown stage could be missing at 
random where some centers did not provide the data; the overall survival for these cases likely would be 
similar to the average survival for all cases. Cases with unknown stage also could reflect data from 
patients not completely staged because they were not good candidates for clinical workup and treatment; 
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the overall survival for these cases would be similar to cases with a more advanced stage. In 2004–2009, 
the survival for cases with unknown stage in our study was lower than the survival for local or regional 
stage, but higher than the survival for distant stage; this pattern suggests that many of the unknown cases 
were likely similar to cases with a more advanced stage. 
 
CDC Cancer Prevention and Control Programs 
The National Comprehensive Cancer Control Program (NCCCP) supports state, tribal, and territory 
programs to develop cancer plans that design and implement activities in cancer prevention and 
control.8,42 State-specific data are critical to inform these cancer control plans and activities. 
While research is conducted to improve clinical care and to reduce racial disparities, the greatest 
impact to reduce lung cancer incidence will come from cancer control efforts directed at primary 
prevention of established risk factors, such as cigarette smoking,43 the inhalation of secondhand smoke 
by nonsmokers,43 indoor radon (a leading cause of lung cancer among non-smokers),44 occupational 
exposures to carcinogens,45 and air pollution.45 
To address lung cancer prevention, mortality, and survival, NCCCP programs develop detailed 
plans to prevent and control cancer for their communities, and the majority include objectives for 
reducing tobacco use and indoor radon exposure. For example, two-thirds of NCCCP programs include 
funding for tobacco control, such as supporting cessation services and smoke-free policies.46 NCCCP 
programs work with a national network of partner organizations to reach populations that tend to be 
heavy smokers.47 Continued and expanded access to tobacco cessation services could increase 
abstinence rates and decrease lung cancer incidence further. 
Several NCCCP programs support activities related to lung cancer screening, including 
awareness through health care provider education, media campaigns, and surveys to better understand 
the status of lung cancer screening in their communities.48 Continued and expanded incorporation of 
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objectives related to USPSTF lung cancer screening recommendations into NCCCP cancer plans could 
increase early detection of lung cancer, thereby improving lung cancer survival.39 NCCCP programs 
could utilize their experiences from other cancer screening programs to impact lung cancer screening 
rates at a population level. Further, as lung cancer screening begins to be fully implemented in the 
United States, NCCCP programs might explore the use of patient navigators to coordinate and improve 
compliance with follow-up visits and annual repeated lung cancer screening.49 
In the future, NCCCP programs also might consider the feasibility of monitoring and evaluating 
the quality of diagnostic, treatment, and survivorship services for patients with lung cancer. By 
improving understanding of lung cancer care and whether advances in care are differentially accessed, 
NCCCP programs may identify effective ways to improve lung cancer survival and reduce disparities in 
various communities. 
NCCCP programs can use lung cancer net survival estimates for their states as an additional 
data resource to support cancer prevention and control.5,38,50 Combined with data on cancer incidence 
and death rates, cancer survival measures can provide a more comprehensive picture of the burden of 
cancer in a population and support public health efforts to reduce cancer health disparities.5,38,50 
 
Strengths and Limitations 
The overview paper5 by Weir et al. for this Supplement describes the strengths and limitations 
that apply to all of the papers in this Supplement, including this analysis of lung cancer survival. 
 
Conclusions 
We found that lung cancer survival improved slightly from 16.4% in 2001–2003 to 19.0% in 2004–2009 
in the United States overall and in most states. It was low even for localized stage (55.1%) in 2004–
2009, and was even lower among blacks (14.9%) than whites (19.4%). We also observed considerable 
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variation (14.5% to 25.2%) in state-specific lung cancer survival in 2004–2009. During 2001–2009, lung 
cancer incidence and mortality in the United States decreased slowly.1,2 Lung cancer mortality trends 
mirror lung cancer incidence trends because of the high fatality rate and low survival for patients with 
lung cancer.51 Given the low survival observed in all states, cancer control efforts directed at primary 
prevention through control of well-established risk factors would be expected to have the greatest impact 
on reducing the burden of lung cancer in the long term. Efforts directed at improving equality of access 
to treatment would be expected to reduce the racial differences in survival in the short to medium term. 
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Table 1. Lung cancer: number of cases (males and females aged 15-99 years) diagnosed 2001–2009 and distribution (%) by SEER Summary 
Stage 2000 at diagnosis, by race and calendar period of diagnosis. 
 2001-2003 2004-2009 
SS2000 
 
All races White Black All races White Black 
No. of patients 
 
449,540 393,257 44,455 955,184 827,550 98,404 
Localized (%) 17.5 17.8 14.8 17.7 18.1 14.9 
Regional  (%) 24.2 24.2 25.0 23.4 23.5 23.1 
Distant (%) 46.8 46.3 49.6 50.9 50.3 54.5 
Unknown (%) 11.5 11.7 10.6 8.0 8.1 7.5 
 
Note: SEER = Surveillance, Epidemiology and End Results (SEER) Program. Information on stage was not available for two states 
(Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004–2009. 
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Table 2. Lung cancer: age-standardized net survival (%) at 1, 3 and 5 years for cases (males and females aged 15-99 years) diagnosed 2001–
2009, by race and calendar period of diagnosis. 
 2001-2003 2004-2009 
 
All races White Black All races White Black 
Years NS 
(%)  
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI 
1 42.5 42.4 - 42.7 42.9 42.7 - 43.1 39.0 38.5 - 39.5 45.6 45.5 - 45.7 45.9 45.8 - 46.0 42.1 41.7 - 42.4 
3 21.6 21.4 - 21.7 21.9 21.8 - 22.1 17.9 17.5 - 18.2 24.5 24.4 - 24.6 24.9 24.8 - 25.0 20.3 19.9 - 20.6 
5 16.4 16.3 - 16.5 16.8 16.6 - 16.9 13.1 12.8 - 13.5 19.0 18.8 - 19.1 19.4 19.2 - 19.5 14.9 14.5 - 15.2 
 
NS = net survival 
CI = confidence interval 
Note: Unstandardized estimates are italicized. 
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Table 3. Lung cancer: 5-year age-standardized net survival (%) for adult cases (males and females aged 15-99 years) diagnosed 2001–2009, 
by SEER Summary Stage 2000 at diagnosis, race, and calendar period of diagnosis. 
 2001-2003 2004-2009 
 All races White Black All races White Black 
SS2000 NS 
(%)  
95% CI NS 
(%)  
95% CI NS 
(%)  
95% CI NS 
(%)  
95% CI NS 
(%)  
95% CI NS 
(%)  
95% CI 
All stages 16.4 16.3 - 16.5 16.8 16.6 - 16.9 13.1 12.8 - 13.5 19.0 18.8 - 19.1 19.4 19.2 - 19.5 14.9 14.5 - 15.2 
Localized 50.2 49.8 - 50.6 51.0 50.5 - 51.4 41.5 40.1 - 42.9 55.1 54.7 - 55.5 55.8 55.3 - 56.2 45.9 44.4 - 47.4 
Regional 20.2 20.0 - 20.5 20.5 20.2 - 20.8 17.1 16.3 - 17.9 26.4 26.0 - 26.7 26.7 26.4 - 27.0 22.0 21.0 - 23.0 
Distant 3.6 3.5 - 3.7 3.5 3.4 - 3.6 3.4 3.2 - 3.7 4.8 4.7 - 4.9 4.7 4.6 - 4.8 4.4 4.1 - 4.7 
Unknown 13.0 12.6 - 13.4 13.1 12.6 - 13.5 11.2 10.2 - 12.3 13.8 13.4 - 14.3 14.0 13.5 - 14.5 11.0 10.0 - 12.1 
 
NS = net survival 
CI = confidence interval 
SEER = Surveillance, Epidemiology and End Results (SEER) Program 
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Figures 
Figure 1. Lung cancer: 5-year age-standardized net survival (%) for adult cases (males and females aged 
15–99 years) diagnosed with lung cancer during 2001–2003 and 2004–2009, and the absolute change 
(%). States are grouped by US Census Region. 
Note: States are ranked within Census Region by the survival estimate for 2004–2009. 
Note: Dark colors – states affiliated with the National Program of Cancer Registries (NPCR); pale colors 
– states affiliated with the Surveillance, Epidemiology and End Results (SEER) Program. *Registries 
affiliated with both federal surveillance programs. Change (%) not plotted because at least one calendar 
period estimate was not age-standardized. 
 
 
Figure 2. Lung cancer: 5-year age-standardized net survival (%) for adult cases (males and females aged 
15–99 years), by state, race, and calendar period of diagnosis. 
Note: The pooled (US) survival for each calendar period is shown by the horizontal (solid) line with 
corresponding 95.0% and 99.8% control limits (dotted lines). 
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Supplemental Tables 
Supplemental Table 1. Lung cancer: number of adult cases (males and females aged 15–99 years) during 
2001–2009, and the distribution (%) by SEER Summary Stage 2000 at diagnosis, race, calendar period, 
and US Census Region, Division, and states. 
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology and End Results (SEER) Program. Information on stage was not available for two states 
(Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004–2009. 
 
Supplemental Table 2. Lung cancer: age-standardized net survival (%) at 1, 3 and 5 years for cases 
(males and females aged 15–99 years) diagnosed during 2001–2009, by race, calendar period of 
diagnosis, and US Census Region, Division, and states. 
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology, and End Results program. Unstandardized estimates are italicized. 
 
Supplemental Table 3. Lung cancer: 5-year age-standardized net survival (%) for adult cases (males and 
females aged 15–99 years) diagnosed during 2001–2009, by SEER Summary Stage 2000 at diagnosis, 
race, calendar period, and US Census Region, Division, and states. 
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology, and End Results program. Information on stage was not available for two states 
(Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009. Unstandardized 
estimates are italicized. 
 
